Clinical Trial · NCT02317393

Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy

Overview

The purpose of this study is to evaluate the contribution of the imaging to the expression of intégrines αvβ3 for the characterization of the residual masses of non-seminoma tumors at the end of chemotherapy. The investigators hope that the results of this first stage of the clinical trial come to consolidate the preclinical results obtained by the investigators team to characterizing the interest and the strong contribution of the use of a tracer resting on the expression of αvβ3 integrine for the diagnosis of simple necrosed mass at the end of the treatment of a non-seminoma tumor, so allowing to defer a surgery to about 40 % of the patients.

Sponsor

Centre Francois Baclesse

Phase

Phase 2

Contacts

Pierre VERA, Dr (PRINCIPAL_INVESTIGATOR)

Nicolas AIDE, Dr (PRINCIPAL_INVESTIGATOR)

Arnaud DOERFLER, Dr (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02317393

Eligibility

Inclusion

* Man or woman aged 18 years or more
Affiliate to a social security system;
Patients with one or several ganglionic or visceral residual masses (\> to 1 cm) after chemotherapy for metastatic non-seminoma testicular tumor, and for which or which a surgery is planned;
Signed written Informed consent

Exclusion

Any medical or psychological condition which could compromise the capacity of the patient to participate in the study;
* Patient deprived of liberty as a result of a justice or administrative decision
Previous or concomitant other cancer in 5 years except basal cell carcinomas